Identifying the links between obesity, insulin resistance and β-cell function: Potential role of adipocyte-derived cytokines in the pathogenesis of type 2 diabetes

European Journal of Clinical Investigation

Volumn 32, Issue SUPPL. 3, 2002, Pages 24-34

  Greenberg, A S ^a   McDaniel, Michael L ^b  

^a TUFTS UNIVERSITY   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Diabetes mellitus type 2; Pathogenesis; PPAR ; Tumour necrosis factor

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; CYTOKINE; TUMOR NECROSIS FACTOR ALPHA; CELL RECEPTOR; INSULIN; NITRIC OXIDE; TRANSCRIPTION FACTOR;

ADIPOCYTE; B LYMPHOCYTE; GLUCOSE HOMEOSTASIS; HUMAN; INSULIN RESISTANCE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PANCREAS ISLET BETA CELL; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; CELL CYCLE; DRUG POTENTIATION; GENETICS; LIPID METABOLISM; LIVER; METABOLISM; PANCREAS ISLET; PATHOPHYSIOLOGY; PHYSIOLOGY; SIGNAL TRANSDUCTION; SKELETAL MUSCLE;

ADIPOCYTES; CELL CYCLE; CYTOKINES; DIABETES MELLITUS, TYPE 2; HUMANS; INSULIN; INSULIN RESISTANCE; ISLETS OF LANGERHANS; LIPID METABOLISM; LIVER; MUSCLE, SKELETAL; NITRIC OXIDE; OBESITY; RECEPTORS, CYTOPLASMIC AND NUCLEAR; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0036616582     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1046/j.1365-2362.32.s3.4.x     Document Type: Review

References (121)

1. Haffner SM, Miettinen H, Gaskill SP, Stern MP. Decreased insulin secretion and increased insulin resistance are independently related to the 7-year risk of NIDDM in Mexican-Americans. Diabetes 1995;44:1386-91.
2. Fujimoto WY. The importance of insulin resistance in the pathogenesis of type 2 diabetes mellitus. Am J Med 2000;108 (Suppl. 6a):9S-14S.
3. Gerich JE. The genetic basis of type 2 diabetes mellitus: impaired insulin secretion versus impaired insulin sensitivity. Endocr Rev 1998;19:491-503.
4. Scheen AJ. From obesity to diabetes: why, when and who? Acta Clin Belg 2000;55:9-15.
5. Caro JF. Clinical review 26: Insulin resistance in obese and nonobese man. J Clin Endocrinol Metab 1991;73:691-5.
6. Campbell PJ, Gerich JE. Impact of obesity on insulin action in volunteers with normal glucose tolerance: demonstration of a threshold for the adverse effect of obesity. J Clin Endocrinol Metab 1990;70:1114-18.
7. Peraldi P, Spiegelman B. TNF-α and insulin resistance: summary and future prospects. Mol Cell Biochem 1998;182:169-75.
8. Mohamed-Ali V, Goodrick S, Rawesh A, Katz DR, Miles JM et al. Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-α in vivo. J Clin Endocrinol Metab 1997;82:4196-200.
9. Bastard JP, Jardel C, Bruckert E, Blondy P, Capeau J, Laville M et al. Elevated levels of interleukin 6 are reduced in serum and subcutaneous adipose tissue of obese women after weight loss. J Clin Endocrinol Metab 2000;85:3338-42.
10. Boden G. Role of fatty acids in the pathogenesis of insulin resistance and NIDDM. Diabetes 1997;46:3-10.
11. Kern PA, Ranganathan S, Li C, Wood L, Ranganathan G. Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance. Am J Physiol Endocrinol Metab 2001;280:E745-E751.
12. Steppan CM, Bailey ST, Bhat S, Brown EJ, Banerjee RR, Wright CM et al. The hormone resistin links obesity to diabetes. Nature 2001;409:307-12.
13. Weyer C, Funahashi T, Tanaka S, Hotta K, Matsuzawa Y, Pratley RE et al. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 2001;86:1930-5.
14. Arnush M, Heitmeier MR, Scarim AL, Marino MH, Manning PT, Corbett JA. IL-1 produced and released endogenously within human islets inhibits beta cell function. J Clin Invest 1998;102:516-26.
15. Zhang S, Kim KH. TNF-alpha inhibits glucose-induced insulin secretion in a pancreatic beta-cell line (INS-1). FEBS Lett 1995;377:237-9.
16. Southern C, Schulster D, Green IC. Inhibition of insulin secretion from rat islets of Langerhans by interleukin-6. An effect distinct from that of interleukin-1. Biochem J 1990;272:243-5.
17. Crespin SR, Greenough WB, Steinberg D. Stimulation of insulin secretion by long-chain free fatty acids. A direct pancreatic effect. J Clin Invest 1973;52:1979-84.
18. Goberna R, Tamarit JJ, Osorio J, Fussganger R, Tamarit J, Pfeiffer EF. Action of B-hydroxy butyrate, acetoacetate and palmitate on the insulin release in the perfused isolated rat pancreas. Horm Metab Res 1974;6:256-60.
19. Streeper RS, Svitek CA, Chapman S, Greenbaum LE, Taub R, O'Brien RM. A multicomponent insulin response sequence mediates a strong repression of mouse glucose-6-phosphatase gene transcription by insulin. J Biol Chem 1997;272:11698-701.
20. Bertrand F, Desbois-Mouthon C, Cadoret A, Prunier C, Robin H, Capeau J et al. Insulin antiapoptotic signaling involves insulin activation of the nuclear factor kappaB-dependent survival genes encoding tumor necrosis factor receptor-associated factor 2 and manganese-superoxide dismutase. J Biol Chem 1999;274:30596-602.
21. Baserga R, Sell C, Porcu P, Rubini M. The role of the IGF-I receptor in the growth and transformation of mammalian cells. Cell Proliferation 1994;27:63-71.
22. Smith U, Axelsen M, Carvalho E, Eliasson B, Jansson PA, Wesslau C. Insulin signaling and action in fat cells: associations with insulin resistance and type 2 diabetes. Ann NY Acad Sci 1999;892:119-26.
23. Zierath JR, Krook A, Wallberg-Henriksson H. Insulin action in skeletal muscle from patients with NIDDM. Mol Cell Biochem 1998;182:153-60.
24. Rother KI, Imai Y, Caruso M, Beguinot F, Formisano P, Accili D. Evidence that IRS-2 phosphorylation is required for insulin action in hepatocytes. J Biol Chem 1998;273:17491-7.
25. Rothenberg PL, Willison LD, Simon J, Wolf BA. Glucose-induced insulin receptor tyrosine phosphorylation in insulin-secreting β-cells. Diabetes 1995;44:802-9.
26. Harbeck MC, Louie DC, Howland J, Wolf BA, Rothenberg PL. Expression of insulin receptor mRNA and insulin receptor substrate 1 in pancreatic islet β-cells. Diabetes 1996;45:711-17.
27. White MF. The insulin signalling system and the IRS proteins. Diabetologia 1997;40 (Suppl. 2):S2-17.
28. White MF. The IRS-signaling system: a network of docking proteins that mediate insulin and cytokine action. Recent Prog Horm Res 1998;53:119-38.
29. Withers DJ, White M. Perspective. The insulin signaling system - a common link in the pathogenesis of type 2 diabetes. Endocrinology 2000;141:1917-21.
30. Kulkarni RN, Winnay JN, Daniels M, Brüning JC, Flier SN, Hanahan D et al. Altered function of insulin receptor substrate-1-deficient mouse islets and cultured β-cell lines. J Clin Invest 1999;104:R69-R75.
31. Withers DJ, Gutierrez JS, Towery H, Burks DJ, Ren JM, Previs S et al. Disruption of IRS-2 causes type 2 diabetes in mice. Nature 1998;391:900-4.
32. Tamemoto H, Kadowaki T, Tobe K, Yagi T, Sakura H, Hayakawa T et al. Insulin resistance and growth retardation in mice lacking insulin receptor substrate-1. Nature 1994;372:182-6.
33. Withers DJ, Burks DJ, Towery HH, Altamuro SL, Flint CL, White MF. IRS-2 coordinates IGF-1 receptor-mediated beta-cell development and peripheral insulin signalling. Nat General 1999;23:32-40.
34. Hotamisligil GS, Murray DL, Choy LN, Spiegelman BM. Tumor necrosis factor α inhibits signaling from the insulin receptor. Proc Natl Acad Sci USA 1994;91:4854-8.
35. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 1993;259:87-91.
36. Dunger A, Cunningham JM, Delaney CA, Lowe JE, Green MH, Bone AJ et al. Tumor necrosis factor-alpha and interferon-gamma inhibit insulin secretion and cause DNA damage in unweaned-rat islets. Extent of nitric oxide involvement. Diabetes 1996;45:183-9.
37. Carswell EA, Old LJ, Kassel RL, Green S, Fiore N, Williamson B. An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci USA 1975;72:3666-70.
38. Bazzoni F, Beutler B. The tumor necrosis factor ligand and receptor families. N Engl J Med 1996;334:1717-25.
39. Paquot N, Castillo MJ, Lefebvre PJ, Scheen AJ. No increased insulin sensitivity after a single intravenous administration of a recombinant human tumor necrosis factor receptor: Fc fusion protein in obese insulin-resistant patients. J Clin Endocrinol Metab 2000;85:1316-19.
40. Kern PA, Saghizadeh M, Ong JM, Bosch RJ, Deem R, Simsolo RB. The expression of tumor necrosis factor in human adipose tissue. Regulation by obesity, weight loss, and relationship to lipoprotein lipase. J Clin Invest 1995;95:2111-19.
41. Hotamisligil GS, Arner P, Caro JF, Atkinson RL, Spiegelman BM. Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. J Clin Invest 1995;95:2409-15.
42. Paolisso G, Rizzo MR, Mazziotti G, Tagliamonte MR, Gambardella A, Rotondi M et al. Advancing age and insulin resistance: role of plasma tumor necrosis factor-α. Am J Physiol 1998;275:E294-E299.
43. Zinman B, Hanley AJ, Harris SB, Kwan J, Fantus IG. Circulating tumor necrosis factor-α concentrations in a native Canadian population with high rates of type 2 diabetes mellitus. J Clin Endocrinol Metab 1999;84:272-8.
44. Edens NK, Fried SK, Kral JG, Hirsch J, Leibel RL. In vitro lipid synthesis in human adipose tissue from three abdominal sites. Am J Physiol 1993;26S:E374-E379.
45. Arner P. Not all fat is alike. Lancet 1998;351:1301-2.
46. Lang CH, Dobrescu C, Bagby GJ. Tumor necrosis factor impairs insulin action on peripheral glucose disposal and hepatic glucose output. Endocrinology 1992;130:43-52.
47. Feingold KR, Serio MK, Adi S, Moser AH, Grunfeld C. Tumor necrosis factor stimulates hepatic lipid synthesis and secretion. Endocrinology 1989;124:2336-42.
48. Nachiappan V, Curtiss D, Corkey BE, Kilpatrick L. Cytokines inhibit fatty acid oxidation in isolated rat hepatocytes: synergy among TNF, IL-6, and IL-1. Shock 1994;1:123-9.
49. Fried SK, Bunkin DA, Greenberg AS. Omental and subcutaneous adipose tissues of obese subjects release interleukin-6: depot difference and regulation by glucocorticoid. J Clin Endocrinol Metab 1998;83:847-50.
50. Kawai T, Takei I, Oguma Y, Ohashi N, Tokui M, Oguchi S et al. Effects of troglitazone on fat distribution in the treatment of male type 2 diabetes. Metabolism 1999;48:1102-7.
51. Carey DG, Galloway D, Dodrell D, Richards J, Jones NP, Zhou B. Rosiglitazone reduces hepatic fat and increases subcutaneous but not intra-abdominal fat depots. Diabetologia 2000;43 (Suppl. 1):A68.
52. Lebovitz HE, Banerji MA. Insulin resistance and its treatment by thiazolidinediones. Recent Prog Horm Res 2001;56:265-94.
53. Path G, Bornstein SR, Gurniak M, Chrousos GP, Scherbaum WA, Hauner H. Human breast adipocytes express interleukin-6 (IL-6) and its receptor system: increased IL-6 production by β-adrenergic activation and effects of IL-6 on adipocyte function. J Clin Endocrinol Metab 2001;86:2281-8.
54. Randle PJ, Garland PB, Hales CN, Newsholme EA. The glucose fatty-acid cycle: its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet 1963;1:785-9.
55. Roden M, Price TB, Perseghin G, Petersen KF, Rothman DL, Cline GW et al. Mechanism of free fatty acid-induced insulin resistance in humans. J Clin Invest 1996;97:2859-65.
56. Rebrin K, Steil GM, Getry L, Bergman RN. Free fatty acid as a link in the regulation of hepatic glucose output by peripheral insulin. Diabetes 1995;44:1038-45.
57. Stephans JM, Pekala PH. Transcriptional repression of the C/EBP-α and GLUT4 genes in 3T3-L1 adipocytes by tumor necrosis factor-α. J Biol Chem 1992;267:13580-4.
58. Hauner H, Petruschke T, RUSS M, Röhrig K, Eckel J. Effects of tumour necrosis factor alpha (TNFα) on glucose transport and lipid metabolism of newly-differentiated human fat cells in cell culture. Diabetologia 1995;38:764-71.
59. Garvey WT, Maianu L, Huecksteadt TP, Birnbaum MJ, Molina JM, Ciaraldi TP. Pretranslational suppression of a glucose transporter protein causes insulin resistance in adipocytes from patients with non-insulin-dependent diabetes mellitus and obesity. J Clin Invest 1991;87:1072-81.
60. Abel ED, Peroni O, Kim JK, Kim Y-B, Boss O, Hadro E et al. Adipose-selective targeting of the GLUT4 gene impairs insulin action in muscle and liver. Nature 2001;409:729-33.
61. Greenberg AS, Nordan RP, McIntosh J, Calvo JC, Scow RO, Jablons D. Interleukin 6 reduces lipoprotein lipase activity in adipose tissue of mice in vivo and in 3T3-L1 adipocytes: a possible role for interleukin 6 in cancer cachexia. Cancer Res 1992;52:4113-16.
62. Tsigos C, Papanicolaou DA, Defensor R, Mitsiadis CS, Kyrou I, Chrousos GP. Dose effects of recombinant human interleukin-6 on pituitary hormone secretion and energy expenditure. Neuroendocrinology 1997;66:54-62.
63. Saghizadeh M, Ong JM, Garvey WT, Henry RR, Kern PA. The expression of TNFα by human muscle. Relationship to insulin resistance. J Clin Invest 1996;97:1111-16.
64. Sigrist S, Bedoucha M, Boelsterli UA. Down-regulation by troglitazone of hepatic tumor necrosis factor-α and interleukin-6 mRNA expression in a murine model of non-insulin-dependent diabetes. Biochem Pharmacol 2000;60:67-75.
65. del Aguila LF, Krishnan RK, Ulbrecht JS, Farrell PA, Correll PH, Lang CH et al. Muscle damage impairs insulin stimulation of IRS-1, PI 3-kinase, and Akt-kinase in human skeletal muscle. Am J Physiol Endocrinol Metab 2000;279:E206-E212.
66. 12 muscle cells. Am J Physiol 1999;276:E849-E855.
67. Youd JM, Rattigan S, Clark MG. Acute impairment of insulin-mediated capillary recruitment and glucose uptake in rat skeletal muscle in vivo by TNF-α. Diabetes 2000;49:1904-9.
68. Patiag D, Gray S, Idris I, Donnelly R. Effects of tumour necrosis factor-α and inhibition of protein kinase C on glucose uptake in L6 myoblasts. Clin Sci (Colch) 2000;99:303-7.
69. Ciaraldi TP, Carter L, Mudaliar S, Kern PA, Henry RR. Effects of tumor necrosis factor-á on glucose metabolism in cultured human muscle cells from nondiabetic and type 2 diabetic subjects. Endocrinology 1998;139:4793-800.
70. Cheung AT, Ree D, Kolls JK, Fuselier J, Coy DH, Bryer-Ash M. An in vivo model for elucidation of the mechanism of tumor necrosis factor-α (TNF-α) induced insulin resistance: evidence for differential regulation of insulin signaling by TNF-α. Endocrinology 1998;139:4928-35.
71. Cheung AT, Wang J, Ree D, Kolls JK, Bryer-Ash M. Tumor necrosis factor-α induces hepatic insulin resistance in obese Zucker {fa/fa) rats via interaction of leukocyte antigen-related tyrosine phosphatase with focal adhesion kinase. Diabetes 2000;49:810-19.
72. Kahn SE. The importance of the β-cell in the pathogenesis of type 2 diabetes mellitus. Am J Med 2000;108 (Suppl. 6a):2S-8S.
73. DeFronzo RA, Bonadonna RC, Ferrannini E, Alberti KG, Zimmet P, DeFronzo RA (eds) Pathogenesis of NIDDM. In: International, Textbook of Diabetes Mellitus. New York: Wiley and Sons 1997, pp. 635-712.
74. Rossetti L, Giaccari A, DeFronzo RA. Glucose toxicity. Diabetes Care 1990;13:610-30.
75. Unger RH. Lipotoxicity in the pathogenesis of obesity-dependent NIDDM. Genetic and clinical implications. Diabetes 1995;44:863-70.
76. McGarry JD, Dobbins RL. Fatty acids, lipotoxicity and insulin secretion. Diabetologia 1999;42:128-38.
77. Cavaghan MK, Ehrmann DA, Polonsky KS. Interactions between insulin resistance and insulin secretion in the development of glucose intolerance. J Clin Invest 2000;106:329-33.
78. 2 and aminoguanidine. A role for peroxisome proliferator-activated receptor γ activation and iNOS expression. J Biol Chem 1999;274:18702-8.
79. Farney AC, Xenos E, Sutherland DE, Widmer M, Stephanian E, Field MJ et al. Inhibition of pancreatic islet beta cell function by tumor necrosis factor is blocked by a soluble tumor necrosis factor receptor. Transplant Proc 1993;25:865-6.
80. Bolaffi JL, Rodd GG, Wang J, Grodsky GM. Interrelationship of changes in islet nicotine adenine dinucleotide, insulin secretion, and cell viability induced by interleukin-1 beta. Endocrinology 1994;134:537-42.
81. Campbell IL, Oxbrow L, Harrison LC. Interferon-gamma: pleiotropic effects on a rat pancreatic beta cell line. Mol Cell Endocrinol 1987;52:161-7.
82. Welsh N, Eizirik DL, Bendtzen K, Sandler S. Interleukin-1 beta-induced nitric oxide production in isolated rat pancreatic islets requires gene transcription and may lead to inhibition of the Krebs cycle enzyme aconitase. Endocrinology 1991;129:3167-73.
83. Corbett JA, Lancaster JR, Sweetland MA, McDaniel ML. Interleukin-1 beta-induced formation of EPR-detectable iron-nitrosyl complexes in islets of Langerhans. Role of nitric oxide in interleukin-1 beta-induced inhibition of insulin secretion. J Biol Chem 1991;266:21351-4.
84. Brunori M, Giuffre A, Sarti P, Stubauer G, Wilson MT. Nitric oxide and cellular respiration. Cell Mol Life Sci 1999;56:549-57.
85. Corbett JA, Wang JL, Sweetland MA, Lancaster JR, McDaniel ML. Interleukin 1 beta induces the formation of nitric oxide by beta-cells purified from rodent islets of Langerhans. Evidence for the beta-cell as a source and site of action of nitric oxide. J Clin Invest 1992;90:2384-91.
86. Corbett JA, Sweetland MA, Wang JL, Lancaster JR, McDaniel ML. Nitric oxide mediates cytokine-induced inhibition of insulin secretion by human islets of Langerhans. Proc Natl Acad Sci USA 1993;90:1731-5.
87. Corbett JA, McDaniel ML. Intraislet release of interleukin 1 inhibits β cell function by inducing β cell expression of inducible nitric oxide synthase. J Exp Med 1995;181:559-68.
88. Kulkarni RN, Bruning JC, Winnay JN, Postic C, Magnuson MA, Kahn CR. Tissue-specific knockout of the insulin receptor in pancreatic beta cells creates an insulin secretory defect similar to that in type 2 diabetes. Cell 1999;96:329-39.
89. Scott PH, Lawrence JC. Attenuation of mammalian target of rapamycin activity by increased cAMP in 3T3-L1 adipocytes. J Biol Chem 1998;273:34496-501.
90. Schmelzle T, Hall MN. TOR, a central controller of cell growth. Cell 2000;103:253-62.
91. Xu G, Marshall CA, Lin TA, Kwon G, Munivenkatappa RB, Hill JR et al. Insulin mediates glucose-stimulated phosphorylation of PHAS-I by pancreatic beta cells. An insulin-receptor mechanism for autoregulation of protein synthesis by translation. J Biol Chem 1998;273:4485-91.
92. Xu G, Kwon G, Marshall CA, Lin TA, Lawrence JCJ, McDaniel ML. Branched-chain amino acids are essential in the regulation of PHAS-I and p70, S6 kinase by pancreatic β cells. A possible role in protein translation and mitogenic signaling. J Biol Chem 1998;273:28178-84.
93. Xu G, Kwon G, Cruz WS, Marshall CA, McDaniel ML. Metabolic regulation by leucine of translation initiation through the mTOR-signaling pathway by pancreatic beta-cells. Diabetes 2001;50:353-60.
94. Marshall BA, Tordjman K, Host HH, Ensor NJ, Kwon G, Marshall CA et al. Relative hypoglycemia and hyperinsulinemia in mice with heterozygous lipoprotein lipase (LPL) deficiency. Islet LPL regulates insulin secretion. J Biol Chem 1999;274:27426-32.
95. Cruz WS, Kwon G, Marshall CA, McDaniel ML, Semenkovich CF. Glucose and insulin stimulate heparin-releasable lipoprotein lipase activity in mouse islets and INS-1 cells. A potential link between insulin resistance and beta-cell dysfunction. J Biol Chem 2001;276:12162-8.
96. Souza SC, de Vargas LM, Yamamoto MT, Lien P, Franciosa MD, Moss LG et al. Overexpression of perilipin A and B blocks the ability of tumor necrosis factor α to increase lipolysis in 3T3-L1 adipocytes. J Biol Chem 1998;273:24665-9.
97. Gerich JE. Redefining the clinical management of type 2 diabetes: matching therapy to pathophysiology. Eur J Clin Invest 2002;32 (Suppl. 3):46-53.
98. Fujiwara T, Wada M, Fukuda K, Fukami M, Yoshioka S, Yoshioka T et al. Characterization of CS-045, a new oral antidiabetic agent, II. Effects on glycemic control and pancreatic islet structure at a late stage of the diabetic syndrome in C57BL/KsJ-db/db mice. Metabolism 1991;40:1213-18.
99. Lee MK, Miles PD, Khoursheed M, Gao KM, Moossa AR, Olefsky JM. Metabolic effects of troglitazone on fructose-induced insulin resistance in the rat. Diabetes 1994;43:1435-9.
100. Eldershaw TP, Rattigan S, Cawthorne MA, Buckingham RE, Colquhoun EQ, Clark MG. Treatment with the thiazolidinedione (BRL 49653) decreases insulin resistance in obese Zucker hindlimb. Horm Metab Res 1995;27:169-72.
101. Lebovitz HE, Dole JF, Patwardhan R, Rappaport EB, Freed MI. Rosiglitazone monotherapy is effective in patients with type 2 diabetes. J Clin Endocrinol Metab 2001;86:280-8.
102. Suter SL, Nolan JJ, Wallace P, Gumbiner B, Olefsky JM. Metabolic effects of new oral hypoglycemic agent CS-045 in NIDDM subjects. Diabetes Care 1992;15:193-203.
103. Iwamoto Y, Kuzuya T, Matsuda A, Awata T, Kumakura S, Inooka G et al. Effect of new oral antidiabetic agent CS-045 on glucose tolerance and insulin secretion in patients with NIDDM. Diabetes Care 1991;14:1083-6.
104. Buchanan TA, Xiang AH, Peters RK, Kjos SL, Berkowitz K, Marroquin A et al. Response of pancreatic β-cells to improved insulin sensitivity in women at high risk for type 2 diabetes. Diabetes 2000;49:782-8.
105. Cavaghan MK, Ehrmann DA, Byrne MM, Polonsky KS. Treatment with the oral antidiabetic agent troglitazone improves β cell responses to glucose in subjects with impaired glucose tolerance. J Clin Invest 1997;100:530-7.
106. Shimabukuro M, Zhou YT, Lee Y, Unger RH. Troglitazone lowers islet fat and restores beta cell function of Zucker diabetic fatty rats. J Biol Chem 1998;273:3547-50.
107. Buckingham RE, Al-Barazanji KA, Toseland CD, Slaughter M, Connor SC, West A et al. Peroxisome proliferator-activated receptor-γ agonist, rosiglitazone, protects against nephropathy and pancreatic islet abnormalities in Zucker fatty rats. Diabetes 1998;47:1326-34.
108. Murphy GJ, Holder JC. PPAR-gamma agonists: therapeutic role in diabetes, inflammation and cancer. Trends Pharmacol Sci 2000;21:469-74.
109. Barillari G, Albonici L, Incerpi S, Bogetto L, Pistritto G, Volpi A et al. Inflammatory cytokines stimulate vascular smooth muscle cells locomotion and growth by enhancing alpha5beta1 integrin expression and function. Atherosclerosis 2001;154:377-85.
110. Jiang C, Ting AT, Seed B. PPAR-γ agonists inhibit production of monocyte inflammatory cytokines. Nature 1998;391:82-6.
111. Ricote M, Li AC, Willson TM, Kelly CJ, Glass CK. The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation. Nature 1998;391:79-82.
112. 2 gene expression and other adipocyte genes. Mol Endocrinol 1998;12:1150-60.
113. Souza SC, Yamamoto MT, Franciosa MD, Lien P, Greenberg AS. BRL 49653 blocks the lipolytic actions of tumor necrosis factor-alpha: a potential new insulin-sensitizing mechanism for thiazolidinediones. Diabetes 1998;47:691-5.
114. Peraldi P, Xu M, Spiegelman BM. Thiazolidinediones block tumor necrosis factor-α-induced inhibition of insulin signaling. J Clin Invest 1997;100:1863-9.
115. Girard J. Is leptin the link between obesity and insulin resistance? Diabetes Metab 1997;23:16-24.
116. Sumner AE, Falkner B, Kushner H, Considine RV. Relationship of leptin concentration to gender, menopause, age, diabetes, and fat mass in African Americans. Obes Res 1998;6:128-33.
117. Considine RV, Sinha MK, Heiman ML, Kriauciunas A, Stephens TW, Nyce MR et al. Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N Engl J Med 1996;334:292-5.
118. Janke J, Engeli S, Gorzelniak K, Luft FC, Sharma AM. Resistin gene expression in human adipocytes is not related to insulin resistance. Obes Res 2002;10:1-5.
119. Funahashi T, Nakamura T, Shimomura I, Maeda K, Kuriyama H, Takahashi M et al. Role of adipocytokines on the pathogenesis of atherosclerosis in visceral obesity. Intern Med 1999;38:202-6.
120. Maeda N, Takahashi M, Funahashi T, Kihara S, Nishizawa H, Kishida K et al. PPARγ ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes 2001;50:2094-9.
121. Yang WS, Jeng CY, Wu TJ, Tanaka S, Funahashi T, Matsuzawa Y et al. Synthetic peroxisome proliferator-activated receptor-γ agonist, rosiglitazone, increases plasma levels of adiponectin in type 2 diabetic patients. Diabetes Care 2002;25:376-80.